All clinical trials, including the Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM) [91] trial, the Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT-1) [92] and Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT-2) [93] trials, as well as the EASE-2/3 [94] Empagliflozin trials, showed that SGLT2i’s promoted reductions in HbA1c, body weight and insulin requirements. Here, INS is linked to diabetes mellitus.